

innovace® (enalapril maleate, MSD)

CONSENSUS

Co-operative North Scandinavian Enalapril Survival Study

... In summary, the CONSENSUS data provide compelling evidence that 'Innovace' reduced mortality due to the progression of heart disease by 50%,¹ improved symptoms, reduced the number of hospital admissions and was well tolerated in patients with severe CHF.

REGULATED PRODUCT INFORMATION

Refer to Data Sheet before prescribing.

INDICATIONS

For congestive heart failure where standard therapy is ineffective or inappropriate. Congestive heart failure (adjunctive therapy).

SAGE AND ADMINISTRATION

Initiation: Initially 5 mg once daily, reduce to 2.5 mg if over 65 years, on diuretics renally impaired. Adjust dose according to response; maintenance usually 10-20 mg once daily. Maximum dose 40 mg daily. Diuretic-treated patients - if possible stop diuretic two to three days before starting 'Innovace'. Resume diuretic if required.

Severe heart failure (adjunctive therapy): Initially 10 mg daily in hospital under medical supervision, easing to the usual maintenance dose of 10-20 mg once daily according to response.

Renal function: May require a lower maintenance dose. 'Innovace' is dialysable.

CONTRA-INDICATIONS

Pregnancy - stop therapy if suspected. Hypersensitivity to 'Innovace'. Patients reacting with oneuritic oedema to previous ACE-inhibitor treatment.

PRECAUTIONS

Assess renal function prior to therapy with 'Innovace' and during therapy where appropriate. Renal insufficiency; renovascular hypertension; possibility of hypotension especially in ischaemic heart disease or cerebrovascular disease; surgery/anaesthesia.

Combination with antihypertensives may increase hypotensive effect. Sometimes increased blood urea and creatinine and/or cases of renal insufficiency if given with diuretics. Minimises thiazide-induced hypokalaemia and hyperuricaemia. Potassium supplements, potassium-sparing diuretics, and potassium-containing salt substitutes are not recommended. Possible reduced response in Afro-Caribbean patients. Use with caution in breast-feeding mothers. Do not use in aortic stenosis, or outflow tract obstruction. Monitor serum levels of lithium, if lithium salts are given.

SIDE EFFECTS

Dizziness, headache. Others include fatigue, asthenia, nausea, diarrhoea, muscle cramps, rash, dysgeusia, cough.

Less commonly, angioneurotic oedema; other hypersensitivity reactions; renal failure; sympto-

matic hypotension (especially if volume-depleted); severe hypotension (more likely if severe heart failure); hyperkalaemia; hypokalaemia; increases in liver enzymes and serum bilirubin (usually reversible on discontinuation of 'Innovace'); paraesthesiae; impotence.

BASIC NHS COST

2.5 mg tablets, £10.00 for bottles of 50.
5 mg tablets, £7.86 for 28-day calendar pack.
10 mg tablets, £11.03 for 28-day calendar pack.
20 mg tablets, £13.10 for 28-day calendar pack.

Product licence numbers:

2.5 mg tablets, 0025/0220; 5 mg tablets, 0025/0194;
10 mg tablets, 0025/0195; 20 mg tablets, 0025/0196.

Issued December 1989.

* denotes registered trademark of Merck & Co., Inc., Rahway, NJ, USA.

References

1. CONSENSUS Trial Study Group, *New Engl. J. Med.*, 1987, **316**, 1429.
2. Kjekshus, J., and Swedberg, K., *Amer. J. Cardiol.*, 1988, **62**, 67A-72A.



(enalapril maleate, MSD)

Once daily in congestive heart failure



Merck Sharp & Dohme Limited, Hertford Road
Hoddesdon, Hertfordshire, EN11 9BU



NEW
Burinex[®] A
 bumetanide / amiloride


Guarding the potassium

Established diuretic power - Desirable potassium conservation

Prescribing Information

Presentation: Burinex A combines the potent loop diuretic bumetanide with the mild potassium sparing diuretic amiloride. Each scored tablet contains 1mg bumetanide and 5 mg amiloride hydrochloride. **Indications:** Burinex A is indicated where a prompt diuresis is required. It is particularly of value in conditions where potassium conservation is important. **Dosage and Administration:** The normal adult dose is 1 to 2 tablets daily. Serum electrolytes and urea should be monitored carefully in the elderly. Burinex A is not recommended for use in children. **Contra-Indications, Warnings, Precautions and Side Effects:** Burinex A is contra-indicated in hyperkalaemia, severe electrolyte imbalance, acute renal insufficiency, severe progressive renal disease, severe liver disease including hepatic pre-coma and adrenocortical insufficiency. Careful monitoring of fluid and electrolyte status, particularly in seriously ill patients, should be carried out. Hyponatraemia, hypochloraemia and raised blood urea may occur or hyperuricaemia, which may precipitate acute attacks of gout. Patients with prostatic hypertrophy or impaired micturition may develop acute retention. The requirement for hypoglycaemic agents may be increased and latent diabetes may become manifest. Potassium supplements or potassium sparing agents

should not be given concurrently. Serum lithium levels may increase with concomitant lithium therapy. Since ACE inhibitors may elevate serum potassium, use with Burinex A is best avoided, especially in the elderly or in renal impairment. Nephrotoxicity of cephalosporin and aminoglycoside antibiotics may be enhanced. Cardiac glycosides or antihypertensive agents may require dose adjustment. Side effects include: gastrointestinal upset, abdominal or muscle pain, electrolyte or fluid depletion, skin rashes, thrombocytopenia. The safety of Burinex A during pregnancy and lactation has not been established. **Product Licence Number:** 0043/0161 **Basic NHS Price:** £3.28/28 tablets




Further information is available from:

Leo Laboratories Limited
 Longwick Road, Princes Risborough
 AYLESBURY
 Bucks HP17 9RR

© Registered Trade Mark

ADCTLY DIFFERENT CALCIUM ANTAGONIST



AMLODIPINE

**Genuine 24 hour control
and a high level of tolerability
from a single daily tablet**





Arythmol.▼ propafenone HCl

First Line, long term.

Proven short¹ and long² term efficacy makes Arythmol a logical first line treatment for ventricular arrhythmias.

Ref: 1 Singh BN et al. Am Heart J 1988; 116(6): 1542-1551 2 Ha Dinh et al. Am Heart J 1988; 115(1): 92-96

▼ **ABBREVIATED PRESCRIBING INFORMATION** **Presentation** White, film coated 150mg and 300mg tablets containing propafenone hydrochloride. **Indications** Prophylaxis and treatment of ventricular arrhythmias. **Dose** Individual maintenance dose should be determined under cardiological surveillance and hospital conditions. **Adults** Initially 150mg three times daily increasing at a minimum of 3 day intervals to 300mg twice daily and, if necessary, to a maximum of 300mg three times daily. **Elderly patients; patients with impaired hepatic or renal function** A reduction in the recommended dose is advisable. **Contraindications** Uncontrolled heart failure, cardiogenic shock (except arrhythmia induced), severe bradycardia, uncontrolled electrolyte disturbances, severe obstructive pulmonary disease, marked hypotension, myasthenia gravis. Unless adequately paced, ARYTHMOL should not be used in the presence of sinus node dysfunction, atrial conduction defects, second degree or greater atrio-ventricular block, bundle branch or distal block. **Precautions** The minor negative inotropic effect of ARYTHMOL may assume importance in patients predisposed to heart failure. Caution should be exercised in patients with obstructive airways disease. Effects of ARYTHMOL may be potentiated if given with other local anaesthetic type agents or agents which depress myocardial activity. Reduced doses of digoxin, warfarin, propranolol and metoprolol may be required when given in combination with ARYTHMOL. Plasma levels of ARYTHMOL may be increased by concomitant administration of cimetidine or quinidine. ARYTHMOL has been shown to decrease pacemaker sensitivity and increase pacing thresholds. ARYTHMOL should not be used during pregnancy. **Side effects** Generally well tolerated. Minor side effects at high doses usually relate to the nervous system and cardiovascular system. Dizziness, nausea, vomiting, fatigue, bitter taste, constipation, diarrhoea, headache, blurred vision, dry mouth may occur. More rarely, bradycardia, sinoatrial, atrioventricular or intraventricular conduction blocks and hypotension may occur. Small risk of proarrhythmic effects. Very rarely hypersensitivity reactions (e.g. skin rash, cholestasis, blood dyscrasias, lupus syndrome) and seizures may occur. All side effects are reversible on discontinuation of treatment. **Product licence numbers** ARYTHMOL tablets 150mg 0169/0015, ARYTHMOL tablets 300mg 0169/0016. **Basic NHS price** ARYTHMOL 150mg × 90 - £19.98, ARYTHMOL 300mg × 60 - £19.98. Further information available from Knoll Ltd, Fleming House, 71 King Street, Maidenhead, Berkshire SL6 1DU.

ARYTHMOL

propafenone HCl
Arythmol is a registered trade mark

knoll

BASF Group

SPECIAL BMA MEMBERS EDITION

MIRROR OF MEDICINE

A HISTORY OF THE BMJ

P. W. J. BARTRIP



The BMJ's 150 year history has taken it from small beginnings in Worcester as the *Provincial Medical and Surgical Journal* to its current position as a major international medical journal. In this authoritative study the historian P W J Bartrip provides a shrewd and perceptive commentary on the BMJ's progress and the events that helped to shape it.

352 pp., illus., Clarendon Press/BMJ,
September 1990

Price to BMA members only: UK £29; Abroad £33. Prices include packing and postage, by air speeded despatch abroad (air mail rates on application). AMEX. Access. Visa credit cards accepted.

Return address for orders: British Medical Journal, PO Box 295, London WC1H 9TE. (Also available in the BMJ/BMA bookshop in BMA House.)

NATIONAL HEART & LUNG INSTITUTE
ROYAL BROMPTON AND NATIONAL
HEART HOSPITAL

CARDIAC DOPPLER ULTRASOUND

3-5 APRIL 1991

A course involving all aspects of cardiac Doppler ultrasound for physicians, technicians and radiologists with a basic knowledge in echocardiography.

A series of lectures, demonstrations and practical sessions will cover the range of cardiac Doppler ultrasound including spectral Doppler ultrasound, transoesophageal echocardiography, intracoronary imaging and computer analysis techniques in adult and congenital heart disease.

Course Fee: £200.00 (to include lunch and all refreshments).

Further details from:
Postgraduate Education Centre
National Heart & Lung Institute
Dovehouse Street
London SW3 6LY

Tel: 071-351 8172 (direct line; 24 hr answering service)
Fax: 071-376 3442

BLOOD PRESSURE MEASUREMENT



VIDEO AND BOOKLET

Produced by the British Hypertension Society, this two part training video first outlines the points to check in assessing equipment and then provides step by step guidance on the correct procedure for blood pressure measurement. The second part displays a sequence of falling mercury sphygmomanometer columns with simultaneous Korotkoff sounds. Observers are asked to make recordings from these and can check their findings against those of a group of experienced observers. Also supplied with the video is a copy of the second edition of *Blood Pressure Measurement*, by J C Petrie, E T O'Brien, W A Littler, M de Swiet, P L Padfield and M J Dillon, which summarises the main points for easy reference and is available separately.

Price: Inland and abroad £24.95 (including VAT in the UK and air mail despatch abroad)

Copies of the second edition of *Blood Pressure Measurement*, are available separately price-inland £1.25; abroad £2.25.

Please enclose payment with order or send us full details of your VISA, MASTERCARD or AMERICAN EXPRESS credit card.

Available from BRITISH MEDICAL JOURNAL, PO Box 295, London WC1H 9TE, any leading medical bookseller or BMJ/BMA bookshop in BMA House.

Operating Worldwide

Relied upon by leading surgeons, Swann-Morton blades are as worldwide as their reputation for quality. Alongside their classic surgical range, there are the "Major" orthopaedic blades, "Minor" disposables, and special blades for cervical biopsy and myringotomy. Most recent is the completely new "Fine" range. Extensively researched, all blades are produced under strict quality control by precise automation, and inspected at every stage. Swann-Morton always have the blade for the task, uniformly correct in shape, size and weight, and durably sharp—that's why they are World-Famous!

**Swann-Morton Limited, Penn Works,
Owlerton Green, Sheffield S6 2BJ, England.
Tel: (0742) 344231. Fax: (0742) 314966. Telex: 547538**

**LEICESTER UNIVERSITY SEMINARS
IN INTERVENTIONAL CARDIOLOGY**

**PERCUTANEOUS INTERVENTION
IN ADULT VALVULAR AND
CONGENITAL HEART DISEASE**

Leicester, 12 April 1991

Topics: Pulmonary Valve and Pulmonary Branch Stenosis, Laser Assisted Valvuloplasty, Ductus Closure, ASD Anatomy, Coarctation, Mitral and Aortic Valvuloplasty.

Faculty: Chan (Leicester), de Giovanni (Birmingham), Dyet (Hull), Firmin (Leicester), Godman (Edinburgh), Leanage (Leicester), Qureshi (London), Starkey (Edinburgh), Treasure (London), Tynan (London), Vahanian (Paris).

Organisers:

Professor D P de Bono and Dr A H Gershlick

For programme and further information contact:
Mrs Fiona Legate, Department of Cardiology,
Glenfield General Hospital, Groby Road,
Leicester. LE3 9QP.

Telephone: (0533) 871471 extn 3038 Fax: (0533) 875792

University of London
Royal Postgraduate Medical School



Hammersmith Echocardiography

13–17th May 1991

A week long course of contemporary echocardiography designed for cardiologists, cardiac technicians and general physicians. This intensive course will consist of lectures from world-wide experts in the field, panel discussions on controversial subjects and demonstrations.

The following topics will be covered:

Physics of modern ultrasound technology • Cardiovascular morphology viewed from the Echo windows (including monoplane and biplane TOE) • Foetal Echocardiography • Congenital Heart Disease • The Elderly Heart • Ischaemic Heart Disease (including Exercise Echocardiography) • Transoesophageal Echocardiography in clinical practice • Valvular Heart Disease • The Role of M-mode Echocardiography in the 90s • Endocarditis • Cardiomyopathies • Intraoperative Echocardiography

Speakers will include:

Professor J Kisslo (US)	Dr SY Ho (London)
Professor JRTC Roelandt (Netherlands)	Dr S Hunter (Newcastle)
Dr G Sutherland (Edinburgh)	Dr J Gibbs (Leeds)
Mr GJ Leech (London)	Dr R Pridie (Harefield)
Dr L Allan (London)	Dr I Simson (London)
Dr RA Foale (London)	Dr M Monaghan (London)
Dr M St John Sutton (London)	Dr R Hall (Cardiff)

Invited Discussants:

Professor P Poole-Wilson (London)	Professor A Maseri (London)
Dr R Underwood (London)	Dr WJ McKenna (London)
Dr CM Oakley (London)	Dr GJ Davies (London)

Course organiser:

Dr P Nihoyannopoulos MD FESC

Course fee:

£350.00
(£280.00 for UK NHS employees)

Further details from:

Telephone: 081 740 3117
081 740 3245

Fax: 081 740 4950

Wolfson Conference Centre
Royal Postgraduate Medical
School
Hammersmith Hospital
Du Cane Road
London W12 0NN